Approval · Notice of Compliance 9011 · 2007
NEUROLITE: Notice of Compliance 9011
Issued September 7, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9011
- Date
- September 7, 2007
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Radiopharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- The transfer of the manufacturing of the final intermediate used in the manufacture of neurolite to a new site
- Therapeutic class
- Radiodiagnostic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEUROLITE | Not yet assigned | — |
Medicinal ingredients
- BICISATE DIHYDROCHLORIDE 0.9 MG per VIAL